Implementing COVID-19 Testing in Massachusetts Phased Reopening Plans

August 12, 2020 12:00 PM - 1:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 8/12/2020 12:00:00 PM 8/12/2020 1:00:00 PM Implementing COVID-19 Testing in Massachusetts Phased Reopening Plans

COVID-19 testing is a significant part of the answer to reopen our economy and our lives – and will remain crucial even after vaccines or therapies eventually become available. Municipalities, companies, universities, hospitals, school systems, and families want to know how and when they could implement testing or be tested so our society can reopen more fully and more confidently. Ideally, we want a highly reliable, rapid test that provides results in minutes. We hear it is taking 7+ days to get a test back due to the current surges in our country and it seems like test companies are way over capacity. How does the MassBio community implement testing? Is it even realistic now? What kind of testing should be implemented? We’ll hear from those who were on the forefront of implementing testing as part of their reopening strategy and get a pulse on how it is going. We’ll also address the shortfalls of current testing and offer strategies to undertake testing as a key component of your reopening plans.

Webinar link will be emailed to participants the day before - you can also access it from the "Live Stream" tab below. This event is for members-only. 

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Webinar, click "live-stream" button to view

COVID-19 testing is a significant part of the answer to reopen our economy and our lives – and will remain crucial even after vaccines or therapies eventually become available. Municipalities, companies, universities, hospitals, school systems, and families want to know how and when they could implement testing or be tested so our society can reopen more fully and more confidently. Ideally, we want a highly reliable, rapid test that provides results in minutes. We hear it is taking 7+ days to get a test back due to the current surges in our country and it seems like test companies are way over capacity. How does the MassBio community implement testing? Is it even realistic now? What kind of testing should be implemented? We’ll hear from those who were on the forefront of implementing testing as part of their reopening strategy and get a pulse on how it is going. We’ll also address the shortfalls of current testing and offer strategies to undertake testing as a key component of your reopening plans.

Webinar link will be emailed to participants the day before - you can also access it from the "Live Stream" tab below. This event is for members-only. 

NOTE: MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

Market Sector Leader in the Mass General Brigham Innovation office
Dr. Miller is a Market Sector Leader in the Mass General Brigham Innovation office. Dr. Miller has 30 years of experience in the clinical laboratory industry and personalized medicine field including serving as Vice President and Head of Personalized Healthcare and Biomarker Strategy, Portfolio and Alliances for AstraZeneca Pharmaceuticals; Executive Vice President and Chief Technology Officer of MolecularMD; and Vice President and General Manager of Genzyme Analytical Services. Dr. Miller also serves as Chair of the Scientific Advisory Board and is a member of the Board of Directors of the medical device company, Biomarker Strategies. He received his Ph.D. in Experimental Pathology from Roswell Park Memorial Institute, a graduate division of the State University of New York at Buffalo. He completed his postdoctoral work in molecular hematology and viral leukemogenesis at Memorial Sloan Kettering Cancer Center and molecular genetics at the University of Miami School of Medicine.